1. Home
  2. SCYX vs FOXX Comparison

SCYX vs FOXX Comparison

Compare SCYX & FOXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • FOXX
  • Stock Information
  • Founded
  • SCYX 1999
  • FOXX 2017
  • Country
  • SCYX United States
  • FOXX United States
  • Employees
  • SCYX N/A
  • FOXX N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • FOXX
  • Sector
  • SCYX Health Care
  • FOXX
  • Exchange
  • SCYX Nasdaq
  • FOXX Nasdaq
  • Market Cap
  • SCYX 36.8M
  • FOXX 39.6M
  • IPO Year
  • SCYX 2014
  • FOXX N/A
  • Fundamental
  • Price
  • SCYX $0.74
  • FOXX $5.32
  • Analyst Decision
  • SCYX
  • FOXX
  • Analyst Count
  • SCYX 0
  • FOXX 0
  • Target Price
  • SCYX N/A
  • FOXX N/A
  • AVG Volume (30 Days)
  • SCYX 170.9K
  • FOXX 6.9K
  • Earning Date
  • SCYX 08-07-2025
  • FOXX 08-15-2025
  • Dividend Yield
  • SCYX N/A
  • FOXX N/A
  • EPS Growth
  • SCYX N/A
  • FOXX N/A
  • EPS
  • SCYX N/A
  • FOXX N/A
  • Revenue
  • SCYX $2,630,000.00
  • FOXX $53,866,257.00
  • Revenue This Year
  • SCYX $463.61
  • FOXX N/A
  • Revenue Next Year
  • SCYX $310.80
  • FOXX N/A
  • P/E Ratio
  • SCYX N/A
  • FOXX N/A
  • Revenue Growth
  • SCYX N/A
  • FOXX 3899.98
  • 52 Week Low
  • SCYX $0.72
  • FOXX $2.45
  • 52 Week High
  • SCYX $2.29
  • FOXX $12.80
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 37.94
  • FOXX N/A
  • Support Level
  • SCYX $0.72
  • FOXX N/A
  • Resistance Level
  • SCYX $0.85
  • FOXX N/A
  • Average True Range (ATR)
  • SCYX 0.05
  • FOXX 0.00
  • MACD
  • SCYX -0.01
  • FOXX 0.00
  • Stochastic Oscillator
  • SCYX 9.61
  • FOXX 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About FOXX Foxx Development Holdings Inc. Common Stock

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.

Share on Social Networks: